Parkinson's disease in GTP cyclohydrolase 1 mutation carriers

Brain

Volumn 137, Issue 9, 2014, Pages 2480-2492

  Mencacci, Niccolò E ^a,b   Isaias, Ioannis U ^c,d   Reich, Martin M ^c   Ganos, Christos ^a,e,f   Plagnol, Vincent ^g   Polke, James M ^h   Bras, Jose ^a   Hersheson, Joshua ^a   Stamelou, Maria ^a,i,j   Pittman, Alan M ^a,k   Noyce, Alastair J ^a,k   Mok, Kin Y ^a   Opladen, Thomas ^l   Kunstmann, Erdmute ^m   Hodecker, Sybille ^e   Münchau, Alexander ^f   Volkmann, Jens ^d   Samnick, Samuel ^c   Sidle, Katie ^a   Nanji, Tina ^h   Sweeney, Mary G ^h   Houlden, Henry ^a   Batla, Amit ^a   Zecchinelli, Anna L ^d   Pezzoli, Gianni ^d   Marotta, Giorgio ⁿ   Lees, Andrew ^k   Alegria, Paulo ^o   Krack, Paul ^p   Cormier Dequaire, Florence ^q,r,s   Lesage, Suzanne ^q,r   Brice, Alexis ^q,r,s   Heutink, Peter ^t   Gasser, Thomas ^t   Lubbe, Steven J ^a   Morris, Huw R ^a   Taba, Pille ^u   Koks, Sulev ^v   Majounie, Elisa ^w   Gibbs, J Raphael ^w   Singleton, Andrew ^w   Hardy, John ^a,k   Klebe, Stephan ^c   Bhatia, Kailash P ^a   Wood, Nicholas W ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d PARKINSON INSTITUTE   (Italy)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f University of Lu Beck   (Germany)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

ⁱ UNIVERSITY OF ATHENS   (Greece)

^j PHILIPPS UNIVERSITY MARBURG   (Germany)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^m UNIVERSITY OF WÜRZBURG   (Germany)

ⁿ FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^o HOSPITAL BEATRIZ ÂNGELO   (Portugal)

^p GRENOBLE UNIVERSITY HOSPITAL   (France)

^q SORBONNE UNIVERSITÉ   (France)

^r CNRS   (France)

^s PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^t UNIVERSITY OF TÜBINGEN   (Germany)

^u UNIVERSITY OF TARTU   (Estonia)

^v Faculty of Medicine   (Estonia)

^w NATIONAL INSTITUTE ON AGING   (United States)

more..

Author keywords

DOPA responsive dystonia; Dopamine; Exome sequencing; GCH1; Parkinson's disease

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; GENOMIC DNA; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; PRAMIPEXOLE; RASAGILINE; ROTIGOTINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DYSKINESIA; DYSTONIA; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DOPA-RESPONSIVE-DYSTONIA; DOPAMINE; EXOME SEQUENCING; GCH1; PARKINSON'S DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DATABASES, GENETIC; EUROPE; FEMALE; GENETIC VARIATION; GTP CYCLOHYDROLASE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PEDIGREE; RISK; UNITED STATES; YOUNG ADULT;

EID: 84906663944     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu179     Document Type: Article

References (56)

1. Assmann B, Surtees R, Hoffmann GF. Approach to the diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia. Ann Neurol 2003; 54 (Suppl 6): S18-24.
2. Bandmann O, Daniel S, Marsden CD, Wood NW, Harding AE. The GTPcyclohydrolase I gene in atypical parkinsonian patients: a clinicogenetic study. J Neurol Sci 1996a; 141: 27-32.
3. Bandmann O, Goertz M, Zschocke J, Deuschl G, Jost W, Hefter H, et al. The phenylalanine loading test in the differential diagnosis of dystonia. Neurology 2003; 60: 700-2.
4. Bandmann O, Nygaard TG, Surtees R, Marsden CD, Wood NW, Harding AE. Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. Hum Mol Genet 1996b; 5: 403-6.
5. Bandmann O, Valente EM, Holmans P, Surtees RA, Walters JH, Wevers RA, et al. Dopa-responsive dystonia: a clinical and molecular genetic study. Ann Neurol 1998; 44: 649-56.
6. Bozi M, Bhatia KP. Paroxysmal exercise-induced dystonia as a presenting feature of young-onset Parkinson's disease. Mov Disord 2003; 18: 1545-7.
7. Ceravolo R, Nicoletti V, Garavaglia B, Reale C, Kiferle L, Bonuccelli U. Expanding the clinical phenotype of DYT5 mutations: is multiple system atrophy a possible one? Neurology 2013; 81: 301-2.
8. Clot F, Grabli D, Cazeneuve C, Roze E, Castelnau P, Chabrol B, et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain 2009; 132: 1753-63.
9. Cobb SA, Wider C, Ross OA, Mata IF, Adler CH, Rajput A, et al. GCH1 in early-onset Parkinson's disease. Mov Disord 2009; 24: 2070-5.
10. Datla KP, Blunt SB, Dexter DT. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 2001; 16: 424-34.
11. Duran R, Mencacci NE, Angeli AV, Shoai M, Deas E, Houlden H, et al. The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov Disord 2013; 28: 232-6.
12. Eggers C, Volk AE, Kahraman D, Fink GR, Leube B, Schmidt M, et al. Are Dopa-responsive dystonia and Parkinson's disease related disorders? A case report. Parkinsonism Relat Disord 2012; 18: 666-8.
13. Furukawa Y, Filiano JJ, Kish SJ. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. Mov Disord 2004; 19: 1256-8.
14. Furukawa Y, Kapatos G, Haycock JW, Worsley J, Wong H, Kish SJ, et al. Brain biopterin and tyrosine hydroxylase in asymptomatic doparesponsive dystonia. Ann Neurol 2002; 51: 637-41.
15. Furukawa Y, Lang AE, Trugman JM, Bird TD, Hunter A, Sadeh M, et al. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology 1998; 50: 1015-20.
16. Furukawa Y, Nygaard TG, Gutlich M, Rajput AH, Pifl C, DiStefano L, et al. Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia. Neurology 1999; 53: 1032-41.
17. Garavaglia B, Invernizzi F, Carbone ML, Viscardi V, Saracino F, Ghezzi D, et al. GTP-cyclohydrolase I gene mutations in patients with autosomal dominant and recessive GTP-CH1 deficiency: identification and functional characterization of four novel mutations. J Inherit Metab Dis 2004; 27: 455-63.
18. Gibb WR, Narabayashi H, Yokochi M, Iizuka R, Lees AJ. New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology 1991; 41: 820-2.
19. Hagenah J, Saunders-Pullman R, Hedrich K, Kabakci K, Habermann K, Wiegers K, et al. High mutation rate in dopa-responsive dystonia: detection with comprehensive GCHI screening. Neurology 2005; 64: 908-11.
20. Hauf M, Cousin P, Solida A, Albanese A, Ghika J, Schorderet D. A family with segmental dystonia: evidence for polymorphism in GTP cyclohydrolase I gene. Movement Disorders 2000; 15 (Suppl.3): 154-5.
21. Hertz JM, Ostergaard K, Juncker I, Pedersen S, Romstad A, Moller LB, et al. Low frequency of Parkin, Tyrosine Hydroxylase, and GTP Cyclohydrolase I gene mutations in a Danish population of earlyonset Parkinson's Disease. Eur J Neurol 2006; 13: 385-90.
22. Hjermind LE, Johannsen LG, Blau N, Wevers RA, Lucking CB, Hertz JM, et al. Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency? Mov Disord 2006; 21: 679-82.
23. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol 2012; 124: 325-38.
24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
25. Hwu WL, Chiou YW, Lai SY, Lee YM. Dopa-responsive dystonia is induced by a dominant-negative mechanism. Ann Neurol 2000; 48: 609-13.
26. Irie S, Kanazawa N, Ryoh M, Mochizuki H, Nomura Y, Segawa M. A case of parkinsonism and dopa-induced severe dyskinesia associated with novel mutation in the GTP cyclohydrolase I gene. Parkinsonism Relat Disord 2011; 17: 769-70.
27. Isaias IU, Marotta G, Hirano S, Canesi M, Benti R, Righini A, et al. Imaging essential tremor. Mov Disord 2010; 25: 679-86.
28. Ito Y, Fujita M, Shimada S, Watanabe Y, Okada T, Kusuoka H, et al. Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models. Synapse 1999; 31: 178-85.
29. Jarman PR, Bandmann O, Marsden CD, Wood NW. GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs. J Neurol Neurosurg Psychiatry 1997; 63: 304-8.
30. Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, et al. Dopamine transporter density measured by [123I]beta-CIT singlephoton emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998; 43: 792-800.
31. Kikuchi A, Takeda A, Fujihara K, Kimpara T, Shiga Y, Tanji H, et al. Arg(184)His mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa-responsive dystonia with parkinsonism: a case report. Mov Disord 2004; 19: 590-3.
32. Kurian MA, Gissen P, Smith M, Heales S Jr, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 2011; 10: 721-33.
33. Lee JY, Yang HJ, Kim JM, Jeon BS. Novel GCH-1 mutations and unusual long-lasting dyskinesias in Korean families with dopa-responsive dystonia. Parkinsonism Relat Disord 2013; 19: 1156-9.
34. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-66.
35. Leuzzi V, Carducci C, Carducci C, Cardona F, Artiola C, Antonozzi I. Autosomal dominant GTP-CH deficiency presenting as a doparesponsive myoclonus-dystonia syndrome. Neurology 2002; 59: 1241-3.
36. Leuzzi V, Carducci C, Chiarotti F, D'Agnano D, Giannini MT, Antonozzi I, et al. Urinary neopterin and phenylalanine loading test as tools for the biochemical diagnosis of segawa disease. JIMD Rep 2013; 7: 67-75.
37. Nair VD, Olanow CW, Sealfon SC. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 2003; 373: 25-32.
38. Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 2011; 134: 3290-8.
39. Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging 2013; 40: 565-73.
40. Nygaard T. An analysis of North American families with dopa-responsive dystonia. In: Segawa M, editor. Hereditary progressive dystonia. London: Parthenon Publishing; 1993a. p. 97-106.
41. Nygaard TG. Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis. Adv Neurol 1993b; 60: 577-85.
42. Nygaard TG, Takahashi H, Heiman GA, Snow BJ, Fahn S, Calne DB. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with doparesponsive dystonia. Ann Neurol 1992; 32: 603-8.
43. Nygaard TG, Trugman JM, de Yebenes JG, Fahn S. Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology 1990; 40: 66-9.
44. Nygaard TG, Wooten GF. Dopa-responsive dystonia: some pieces of the puzzle are still missing. Neurology 1998; 50: 853-5.
45. Opladen T, Hoffmann G, Horster F, Hinz AB, Neidhardt K, Klein C, et al. Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Mov Disord 2011; 26: 157-61.
46. Parkkinen L, O'Sullivan SS, Kuoppamaki M, Collins C, Kallis C, Holton JL, et al. Does levodopa accelerate the pathologic process in Parkinson disease brain? Neurology 2011; 77: 1420-6.
47. Plagnol V, Nalls M, Bras JM, Hernandez DG, Sharma M, Sheerin UM, et al. A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet 2011; 7: e1002142.
48. Saunders-Pullman R, Blau N, Hyland K, Zschocke J, Nygaard T, Raymond D, et al. Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test. Mol Genet Metab 2004; 83: 207-12.
49. Segawa M, Nomura Y, Yukishita S, Nishiyama N, Yokochi M. Is phenotypic variation of hereditary progressive dystonia with marked diurnal fluctuation/dopa-responsive dystonia (HPD/DRD) caused by the difference of the locus of mutation on the GTP cyclohydrolase 1 (GCH-1) gene? Adv Neurol 2004; 94: 217-23.
50. Snow BJ, Nygaard TG, Takahashi H, Calne DB. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann Neurol 1993; 34: 733-8.
51. Takahashi H, Levine RA, Galloway MP, Snow BJ, Calne DB, Nygaard TG. Biochemical and fluorodopa positron emission tomographic findings in an asymptomatic carrier of the gene for dopa-responsive dystonia. Ann Neurol 1994; 35: 354-6.
52. Tassin J, Durr A, Bonnet AM, Gil R, Vidailhet M, Lucking CB, et al. Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain 2000; 123: 1112-21.
53. Trender-Gerhard I, Sweeney MG, Schwingenschuh P, Mir P, Edwards MJ, Gerhard A, et al. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 2009; 80: 839-45.
54. Turjanski N, Bhatia K, Burn DJ, Sawle GV, Marsden CD, Brooks DJ. Comparison of striatal 18F-dopa uptake in adult-onset dystoniaparkinsonism, Parkinson's disease, and dopa-responsive dystonia. Neurology 1993; 43: 1563-8.
55. Vaarmann A, Kovac S, Holmstrom KM, Gandhi S, Abramov AY. Dopamine protects neurons against glutamate-induced excitotoxicity. Cell Death Dis 2013; 4: e455.
56. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164.